Skip to main content
Retour
Watch Compare

Mereo BioPharma Group plc

Qualité des données : 100%
MREO
Nasdaq Manufacturing Chemicals
0,32 €
▼ 0,00 € (-0,41%)
Cap. Boursière: 50,74 M
Prix
0,32 €
Cap. Boursière
50,74 M
Fourchette du Jour
0,31 € — 0,32 €
Fourchette 52 Semaines
0,20 € — 3,05 €
Volume
940 918
Ouverture 0,32 €
Moyenne 50J / 200J
0,39 €
18,88% below
Moyenne 50J / 200J
1,45 €
78,01% below

Quick Summary

Points Clés

Negative free cash flow of -30,99 M
Capital efficient — spends only 4,00% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-83,11%
En dessous de la moyenne du secteur (-53,41%)
ROIC-61,73%
Net Margin-8375,60%
Op. Margin-8021,40%

Sécurité

Debt / Equity
N/A
Current Ratio8,71
Interest Coverage-157,28

Valorisation

PE (TTM)
-1,21
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio1,09
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,2 -1,5
P/B 1,1 1,6
ROE % -83,1 -53,4
Net Margin % -8375,6 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0,49% weight
CANC logo CANC Tema Oncology ETF
0,47% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) -77,64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 500 000,0 Net Income (TTM) -41,88 M
ROE -83,11% ROA -72,06%
Gross Margin N/A Operating Margin -8021,40%
Net Margin -8375,60% Free Cash Flow (TTM) -30,99 M
ROIC -61,73% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,71
Interest Coverage -157,28 Asset Turnover 0,01
Working Capital 46,39 M Tangible Book Value 45,96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,21 Forward P/E N/A
P/B Ratio 1,09 P/S Ratio 101,48
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -61,08%
Market Cap 50,74 M Enterprise Value 2,04 M
Per Share
EPS (Diluted TTM) -0,05 Revenue / Share 0,00
FCF / Share -0,19 OCF / Share -0,19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 4,00% FCF Conversion 74,00%
SBC-Adj. FCF -39,10 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 500 000,0 0,0 10,00 M
Net Income -41,88 M -43,25 M -29,47 M
EPS (Diluted) -0,05 -0,06 -0,04
Gross Profit — — —
Operating Income -40,11 M -47,36 M -28,42 M
EBITDA — — —
R&D Expenses 17,77 M 20,93 M 17,42 M
SG&A Expenses — — —
D&A — — —
Interest Expense 255 000,0 1,37 M 2,88 M
Income Tax 0,0 0,0 -532 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 45,92 M 76,39 M 66,50 M
Total Liabilities 5,00 M 15,42 M 15,96 M
Shareholders' Equity 40,92 M 60,97 M 50,54 M
Total Debt — — —
Cash & Equivalents 40,99 M 69,80 M 57,42 M
Current Assets 45,02 M 74,76 M 63,76 M
Current Liabilities 4,30 M 13,85 M 9,49 M